TAMAVAQ NeoVaccine

TAMAVAQ NeoVaccine is a **personalized neoantigen peptide vaccine** designed using artificial intelligence and quantum molecular modeling for the treatment of glioblastoma. It is intended to stimulate the patient's immune system to recognize and attack tumor-specific neoantigens—mutations unique to a patient's cancer cells—thereby achieving highly targeted immune activation and tumor cell eradication. It is administered to patients after completion of chemoradiation and before maintenance temozolomide cycles. Early clinical data suggest potential benefits in immune activation and tumor targeting. The vaccine is developed using individualized tumor profiles to select patient-specific neoantigen peptides for vaccine formulation, reflecting an advanced approach in cancer immunotherapy[1][2][3][4][6][8][10].

Brand names

TAMAVAQ NeoVaccine

Other names

TAMAVAQ NeoVaccineTamavaq Neoantigen Vaccine